FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
SELANKGIGARESEARCH

SELANK · SUBTOPIC · SAFETY PROFILE

SELANK Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of SELANK.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of SELANK. Severity, frequency, and attribution depend on the source publication.

  • Mild nasal irritation (intranasal route)
  • Headache reported
  • Limited Western safety data

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for SELANK.

  • GABAergic medications (theoretical · unstudied combination)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for SELANK in the published record:

  • Pregnancy/lactation (unstudied in Western literature)

FDA REGULATORY STATUS

Not FDA-approved. Research-use only in the United States.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List (2026).

SAFETY Q+A FROM LITERATURE

Is Selank FDA-approved?

No. Selank is research-use only in the United States. It is registered as a research and anxiolytic compound within the Russian Federation under a domestic pharmaceutical authority.

Is Selank banned in sports?

Not currently listed on the WADA Prohibited List as of 2026.

Side effects of Selank?

Limited Western safety data. Russian literature describes mild nasal irritation and rare headache at standard intranasal doses.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

  • Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol 2003. link
  • Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Synthetic Peptides as Promising Anxiolytics of New Generation: Experimental and Clinical Justification. Acta Naturae 2018. link

RELATED PAGES

SELANK OVERVIEWMECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19

© 2026 GigaCompounds LLC · For Laboratory Research Use Only